TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2254769

Group type: EXPERIMENTAL
Intervention: Self-administered diet history questionnaire
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual diet (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-fat diet (Intervention)
Number of subjects: 0
Study: 140786

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide acetone gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzoyl peroxide lotion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin A acid cream
Number of subjects: 0
Study: 30442437

Group type: EXPERIMENTAL
Intervention: l-carnitine administration (1000mg of oral liquid l-carnitine once daily for 8 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no l-carnitine administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: l-carnitine administration
Number of subjects: 0
Study: 29703223

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) cycling
Number of subjects: 19

Group type: COMPARATOR
Intervention: Passive range of movements (PROM)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Passive cycle-ergometry
Number of subjects: 19

Group type: COMPARATOR
Intervention: Quadriceps electrical stimulation
Number of subjects: 19
Study: 27598802

Group type: EXPERIMENTAL
Intervention: 3 months initial chemotherapy (CT)
Number of subjects: 2687

Group type: COMPARATOR
Intervention: 6 months initial chemotherapy (CT)
Number of subjects: 2687

Group type: COMPARATOR
Intervention: No initial chemotherapy (CT)
Number of subjects: 2687

Group type: EXPERIMENTAL
Intervention: Trial VI local failures
Number of subjects: 2687

Group type: EXPERIMENTAL
Intervention: Trial VII local failures
Number of subjects: 2687

Group type: EXPERIMENTAL
Intervention: Trial VI regional/distant failures
Number of subjects: 2687

Group type: EXPERIMENTAL
Intervention: Trial VII regional/distant failures
Number of subjects: 2687
Study: 24512461

Group type: EXPERIMENTAL
Intervention: Merocel (nasal dressing without airway)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Transseptal suture
Number of subjects: 150

Group type: COMPARATOR
Intervention: Internal nasal splint
Number of subjects: 150
Study: 22098260

Group type: COMPARATOR
Intervention: Healthy control participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individuals with cocaine use disorders
Number of subjects: 0
Study: 19129719

Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Normal ventilation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hypoventilation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study: 17611249

Group type: EXPERIMENTAL
Intervention: Risk prediction model from the FOSIDIAL trial
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Baseline variables in multivariate model
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Indirect associations with CVE
Number of subjects: 397
Study: 15673863

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture initiated 30 min before induction (Preinduction)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture initiated after induction (At-induction)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (no acupuncture, electrodes positioned near acupoints)
Number of subjects: 7
Study: 11926556

Group type: EXPERIMENTAL
Intervention: Lanreotide 0.5 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9790077

Group type: EXPERIMENTAL
Intervention: Polyacrylonitrile (AN69) membrane plus subcutaneous EPO after HD
Number of subjects: 11

Group type: COMPARATOR
Intervention: Cuprophan membrane plus subcutaneous EPO after HD
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: AN69 membrane plus subcutaneous EPO after HD plus intravenous EPO immediately before HD
Number of subjects: 11

Group type: COMPARATOR
Intervention: Cuprophan membrane plus subcutaneous EPO after HD plus intravenous EPO immediately before HD
Number of subjects: 11
Study: 7628284

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 2116156

Group type: EXPERIMENTAL
Intervention: i.v. midazolam only
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: i.v. midazolam with antagonism by flumazenil
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: infusion of propofol
Number of subjects: 39
Study: 834796

Group type: EXPERIMENTAL
Intervention: Alpha enhancement condition
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alpha suppression condition
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 40
Study: 30610443

Group type: EXPERIMENTAL
Intervention: Carbohydrate plus casein protein hydrolysate (PRO)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Carbohydrate only (CHO)
Number of subjects: 18
Study: 28074795

Group type: EXPERIMENTAL
Intervention: Grape Seed Extract (GSE) 100 mg every 6 hours orally, 24 hours before operation
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Vitamin C 25 mg/kg through CPB during surgery
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group with no treatment
Number of subjects: 87
Study: 25893978

Group type: EXPERIMENTAL
Intervention: 5‐min training session in reaching (experimental group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 16
Study: 22814896

Group type: EXPERIMENTAL
Intervention: PDT + SRP
Number of subjects: 2

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 2
Study: 22059446

Group type: EXPERIMENTAL
Intervention: Web-based video-driven computer-tailored approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web-based text-driven computer-tailored approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-tailored generic advice (Control)
Number of subjects: 0
Study: 19118788

Group type: EXPERIMENTAL
Intervention: Neuromuscular intervention
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Strain/counter‐strain technique
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study: 17971864

Group type: EXPERIMENTAL
Intervention: dihydroartemisinin‐piperaquine
Number of subjects: 522

Group type: COMPARATOR
Intervention: mefloquine‐artesunate
Number of subjects: 522
Study: 15262189

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 11576098

Group type: EXPERIMENTAL
Intervention: Bloodletting acupuncture before extubation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 60
Study: 9688727

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of estrogen and progesterone therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: No hormone replacement therapy (No HRT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ERT
Number of subjects: 24

Group type: COMPARATOR
Intervention: No HRT
Number of subjects: 24
Study: 1681781

Group type: EXPERIMENTAL
Intervention: naltrexone hydrochloride (50 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: propoxyphene hydrochloride (260 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 7121090

Group type: EXPERIMENTAL
Intervention: Self-care education program
Number of subjects: 900

Group type: COMPARATOR
Intervention: Control group (randomized)
Number of subjects: 900
Study: 31005396

Group type: EXPERIMENTAL
Intervention: 30 mg of intravenous ketorolac plus oxygen at 15 l/min through a non‐rebreather mask (NRB)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 30 mg of intravenous ketorolac plus 7 l/min of oxygen through a 60% venturi mask
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 30 mg of intravenous ketorolac plus 4 l/min of oxygen through a nasal cannula
Number of subjects: 136

Group type: COMPARATOR
Intervention: 30 mg of intravenous ketorolac and room air
Number of subjects: 136
Study: 31070473

Group type: COMPARATOR
Intervention: Underweight boys compared to obese boys
Number of subjects: 25321

Group type: COMPARATOR
Intervention: Healthy weight boys compared to obese boys
Number of subjects: 25321

Group type: COMPARATOR
Intervention: Overweight boys compared to obese boys
Number of subjects: 25321

Group type: COMPARATOR
Intervention: Healthy weight girls compared to underweight girls
Number of subjects: 25321

Group type: COMPARATOR
Intervention: Overweight girls compared to underweight girls
Number of subjects: 25321

Group type: COMPARATOR
Intervention: Obese girls compared to underweight girls
Number of subjects: 25321
Study: 27421767

Group type: EXPERIMENTAL
Intervention: Full access to m4RH
Number of subjects: 0

Group type: COMPARATOR
Intervention: Limited access to m4RH
Number of subjects: 0
Study: 27064274

Group type: EXPERIMENTAL
Intervention: ToyBox-intervention (kindergarten-based, family-involved intervention)
Number of subjects: 4964

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 4964
Study: 24378381

Group type: EXPERIMENTAL
Intervention: Symax™ implant
Number of subjects: 50

Group type: COMPARATOR
Intervention: Omnifit(®) stem
Number of subjects: 50
Study: 21604858

Group type: EXPERIMENTAL
Intervention: Institutional adjunctive instruction condition
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control condition (no institutional adjunctive instruction)
Number of subjects: 94
Study: 20056221

Group type: EXPERIMENTAL
Intervention: Acupressure on the Shenmen point (HT7) for 5 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Light touch on the HT7 points (control)
Number of subjects: 50
Study: 18703936

Group type: EXPERIMENTAL
Intervention: Quetiapine plus fluoxetine
Number of subjects: 114

Group type: COMPARATOR
Intervention: Fluoxetine plus placebo
Number of subjects: 114
Study: 15714986

Group type: EXPERIMENTAL
Intervention: 5-alpha reductase inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selenium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0
Study: 12595861

Group type: EXPERIMENTAL
Intervention: Abciximab (0.125 mg/kg) administered twice at 10-minute intervals with UFH (70 U/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Abciximab (0.125 mg/kg) administered twice at 10-minute intervals with dalteparin (60 IU/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Receptor occupancy assay and PAC1 binding assay
Number of subjects: 40
Study: 10319778

Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway
Number of subjects: 50

Group type: COMPARATOR
Intervention: Laryngeal mask airway
Number of subjects: 50
Study: 9174313

Group type: EXPERIMENTAL
Intervention: Propofol + Ketamine (P + K)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol (P)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 1586385

Group type: EXPERIMENTAL
Intervention: 400 mg erythromycin acistrate enteric coated tablets b.i.d. for 4 days after overnight fast
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 400 mg erythromycin acistrate enteric coated tablets b.i.d. for 4 days after a light breakfast
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 400 mg erythromycin acistrate enteric coated tablets b.i.d. for 4 days after a heavy breakfast
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 400 mg erythromycin acistrate enteric coated tablets b.i.d. for 4 days (steady state)
Number of subjects: 14
Study: 3702224

Group type: EXPERIMENTAL
Intervention: 45 kcal/kg/day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 35 kcal/kg/day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 25 kcal/kg/day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 15 kcal/kg/day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.55 to 0.60 g protein/kg/day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Approximately 35 kcal/kg/day
Number of subjects: 6
Study: 29658822

Group type: EXPERIMENTAL
Intervention: Stress management training (3 x 90 minutes)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Stress management training
Number of subjects: 286
Study: 27680597

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combination of gabapentin and oxybutynin
Number of subjects: 44
Study: 24878745

Group type: EXPERIMENTAL
Intervention: Basic artichoke puree exposure (5-10 times)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Sweetened artichoke puree exposure (5-10 times)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Added energy artichoke puree exposure (5-10 times)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Repeated exposure to artichoke puree
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Age as a predictor of eating pattern
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Enjoyment of food and satiety responsiveness
Number of subjects: 332
Study: 22682768

Group type: EXPERIMENTAL
Intervention: Mifepristone-misoprostol (n=220) - 200mg mifepristone on day 1 and 800 μg buccal misoprostol followed by placebo 3 hours later on day 2
Number of subjects: 441

Group type: COMPARATOR
Intervention: Misoprostol-only (n=221) - placebo on day 1 and 1600 μg of misoprostol (2 doses of 800 μg, given 3 hours apart) on day 2
Number of subjects: 441

Group type: COMPARATOR
Intervention: Misoprostol-only (n=221)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Mifepristone-misoprostol (n=220)
Number of subjects: 441
Study: 20689194

Group type: EXPERIMENTAL
Intervention: iso-amyl cyanoacrylate
Number of subjects: 10

Group type: COMPARATOR
Intervention: 6/0 polyglactin
Number of subjects: 10
Study: 17508037

Group type: EXPERIMENTAL
Intervention: Neuroprotection strategies
Number of subjects: 0
Study: 16213288

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) plus 1 g/d Mycophenolate mofetil (MMF)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Tacrolimus (TAC) plus 2 g/d Mycophenolate mofetil (MMF)
Number of subjects: 173
Study: 12236848

Group type: EXPERIMENTAL
Intervention: St John's wort extract (255-285 mg, 900 micro g hypericin content)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10865914

Group type: EXPERIMENTAL
Intervention: Fluconazole (FCA)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Amphotericin B/flucytosine (ABF)
Number of subjects: 98
Study: 7671898

Group type: EXPERIMENTAL
Intervention: Amiodarone intravenously (n = 26)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Digoxin (n = 24)
Number of subjects: 50
Study: 1776540

Group type: EXPERIMENTAL
Intervention: Health Habits Questionnaire
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Alcohol Questionnaire
Number of subjects: 306

Group type: COMPARATOR
Intervention: Chart screening method
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: CAGE screening
Number of subjects: 306

Group type: COMPARATOR
Intervention: Correlation between CAGE and chart screening
Number of subjects: 306
Study: 6781808

Group type: EXPERIMENTAL
Intervention: Methadone 15 mg . HCl
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31562774

Group type: EXPERIMENTAL
Intervention: Bioavailable gluconate chelated 0.454% stannous fluoride (SnF2) dentifrice
Number of subjects: 2890
Study: 27405619

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC) 750 mg/day, titrated up to 2250 mg/day
Number of subjects: 2309

Group type: COMPARATOR
Intervention: Calcium carbonate (CC) 3 g/day, titrated to achieve serum P levels of 3.5-6.0 mg/dL
Number of subjects: 2309
Study: 25265197

Group type: EXPERIMENTAL
Intervention: High-conflict condition (Iowa Gambling Task with high loss frequency and high long-term outcome)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Low-conflict condition (Iowa Gambling Task with low loss frequency and high long-term outcome)
Number of subjects: 86
Study: 23652489

Group type: COMPARATOR
Intervention: Physical activity > 7 hours/week
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Higher serum triglycerides
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Waist circumference in the top quartile
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Waist circumference in the middle quartiles
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Lower levels of serum HDL
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Moderately elevated triglycerides
Number of subjects: 888
Study: 21359925

Group type: EXPERIMENTAL
Intervention: Preconditioning acupuncture (PA)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Immediate acupuncture (IA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No acupuncture treatment (Group C)
Number of subjects: 80
Study: 19699111

Group type: EXPERIMENTAL
Intervention: Clofazimine 100 mg daily for 30 days, then 100 mg every other day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Colchicine 0.5 mg 3 times daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo 1 pill 2 times daily
Number of subjects: 23
Study: 17455139

Group type: EXPERIMENTAL
Intervention: Protective ventilation with reduced tidal volumes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mechanical ventilation
Number of subjects: 0
Study: 15559341

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11455733

Group type: EXPERIMENTAL
Intervention: rBPI21
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9495416

Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine hydrochloride 1:200,000 epinephrine with sodium bicarbonate
Number of subjects: 38

Group type: COMPARATOR
Intervention: 1.5% lidocaine hydrochloride 1:200,000 epinephrine without sodium bicarbonate
Number of subjects: 38
Study: 7799341

Group type: EXPERIMENTAL
Intervention: D-penicillamine (intermittent treatment, every Monday, Wednesday, and Friday)
Number of subjects: 76

Group type: COMPARATOR
Intervention: D-penicillamine (daily treatment)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both daily and intermittent D-penicillamine treatments
Number of subjects: 76
Study: 2899140

Group type: EXPERIMENTAL
Intervention: VEPA (vincristine, cyclophosphamide, prednisolone, and doxorubicin)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: VEPA-M (VEPA plus methotrexate)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Low-risk group
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Moderate-risk group
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: High-risk group
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Poor performance status (PS) and high lactate dehydrogenase (LDH) level
Number of subjects: 81
Study: 31454502

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.8 mL, 36 mg lidocaine HCl and 0.0225 mg epinephrine)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Tramadol (1.8 mL, 50 mg tramadol HCl and 0.0225 mg epinephrine diluted to 1.8 mL by distilled water)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 32
Study: 30481895

Group type: EXPERIMENTAL
Intervention: Simplified skeletal maturity scoring (SSMS)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Thumb ossification composite index (TOCI)
Number of subjects: 500
Study: 28830404

Group type: EXPERIMENTAL
Intervention: Single-session group (30 min treadmill exercise, 3 days/week for 12 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Multiple-session group (3 sessions of 10 min exercise, 3 days/week for 12 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 36
Study: 25072444

Group type: EXPERIMENTAL
Intervention: Antiviral therapy (adefovir 10 mg/d)
Number of subjects: 200

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 200
Study: 23632053

Group type: EXPERIMENTAL
Intervention: PIL approach (80 mg methylprednisolone)
Number of subjects: 37

Group type: COMPARATOR
Intervention: MIL approach (80 mg methylprednisolone)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: PIL approach
Number of subjects: 37
Study: 20430702

Group type: EXPERIMENTAL
Intervention: Real rTMS (r‐rTMS)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham rTMS (s‐rTMS)
Number of subjects: 23
Study: 18086075

Group type: EXPERIMENTAL
Intervention: Ambu AuraOnce Laryngeal Mask
Number of subjects: 40

Group type: COMPARATOR
Intervention: LMA Classic
Number of subjects: 40
Study: 16174713

Group type: EXPERIMENTAL
Intervention: Kisspeptin-54 infusion (4 pmol/kg x min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline infusion (0.9%)
Number of subjects: 6
Study: 12708955

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11061250

Group type: COMPARATOR
Intervention: NIH Stroke Scale (NIHSS) >17 plus atrial fibrillation
Number of subjects: 0

Group type: COMPARATOR
Intervention: NIHSS >22 at 24 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: NIHSS >16 at 7 to 10 days
Number of subjects: 0
Study: 8902860

Group type: EXPERIMENTAL
Intervention: Nebulized terbutaline (2 ml solution diluted with 2 ml 0.9% saline for inhalation over 10 minutes)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Injected epinephrine (0.01 ml/kg of 1:1000 epinephrine, maximum 0.3 ml, subcutaneous injection)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Injected epinephrine (for patients with initial FEV1 lower than 60% of predicted value)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Injected epinephrine
Number of subjects: 90
Study: 1867917

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with 400 mg cimetidine
Number of subjects: 122

Group type: COMPARATOR
Intervention: Intermittent therapy with cimetidine
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Continuous maintenance therapy
Number of subjects: 122

Group type: COMPARATOR
Intervention: Intermittent therapy
Number of subjects: 122
Study: 7003696

Group type: EXPERIMENTAL
Intervention: 0.4% SnF2 toothpaste
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo toothpaste (no fluoride or stannous ions)
Number of subjects: 0
Study: 30633334

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) 3 times per week for 50 weeks (20 weeks supervised, 30 weeks self-administered)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 158
Study: 27866283

Group type: EXPERIMENTAL
Intervention: Theta/beta neurofeedback training (4-8 Hz for theta and 13-20 Hz for beta)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Theta/beta neurofeedback training
Number of subjects: 38